share_log

Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M

Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M

Karyopharm Therapeutics重申2024年的收入指导为1.4亿至1.6亿美元,而市场共识为1.4652亿美元,其中包括1亿至1.2亿美元的美国XPOVIO净产品收入指导
Benzinga ·  05/08 07:39

Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M

Karyopharm Therapeutics重申2024年的收入指导为1.4亿至1.6亿美元,而市场共识为1.4652亿美元,其中包括1亿至1.2亿美元的美国XPOVIO净产品收入指导

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发